{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=7", "query": { "condition": "Genetic Change", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 1794, "total_pages": 180, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T02:35:49.060Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06378658", "title": "A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Non-small Cell Lung Cancer", "EGFR Mutation", "HER2 Mutation", "Healthy Volunteers" ], "interventions": [ { "name": "BAY2927088", "type": "DRUG" }, { "name": "Esomeprazole", "type": "DRUG" }, { "name": "Food", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 21, "start_date": "2024-03-29", "completion_date": "2024-06-11", "has_results": false, "last_update_posted_date": "2024-07-05", "last_synced_at": "2026-11-11T02:35:49.060Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06378658" }, { "nct_id": "NCT07216352", "title": "Evaluate the Safety and Efficacy of a Topical Serum (AGE Serum) in Improving Visible Signs of Aging", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Laxity; Skin" ], "interventions": [ { "name": "AGE Serum", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Goldman, Butterwick, Fitzpatrick and Groff", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "25 Years to 50 Years" }, "enrollment_count": 25, "start_date": "2025-10-25", "completion_date": "2026-05-30", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-11-11T02:35:49.060Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216352" }, { "nct_id": "NCT04953104", "title": "ARID1A and/or KDM6A Mutation and CXCL13 Expression", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Bladder Urothelial Carcinoma", "Recurrent Renal Pelvis Urothelial Carcinoma", "Recurrent Ureter Urothelial Carcinoma", "Recurrent Urethral Urothelial Carcinoma", "Recurrent Urothelial Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Unresectable Bladder Urothelial Carcinoma", "Unresectable Renal Pelvis Urothelial Carcinoma", "Unresectable Ureter Urothelial Carcinoma", "Unresectable Urethral Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Relatlimab", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-09-21", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-11T02:35:49.060Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04953104" }, { "nct_id": "NCT07215416", "title": "Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ataxia Telangiectasia" ], "interventions": [ { "name": "Antisense oligonucleotide targeting the ATM gene", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Timothy Yu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "0 Years to 17 Years" }, "enrollment_count": 10, "start_date": "2026-08", "completion_date": "2036-12", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-11-11T02:35:49.060Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07215416" }, { "nct_id": "NCT03340506", "title": "Dabrafenib and/or Trametinib Rollover Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Melanoma", "Non Small Cell Lung Cancer", "Solid Tumor", "Rare Cancers", "High Grade Glioma" ], "interventions": [ { "name": "dabrafenib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 100, "start_date": "2018-01-26", "completion_date": "2032-12-28", "has_results": false, "last_update_posted_date": "2026-11-10", "last_synced_at": "2026-11-11T02:35:49.060Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Bethesda, Maryland • Columbus, Ohio + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03340506" }, { "nct_id": "NCT03499353", "title": "Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early Breast Cancer" ], "interventions": [ { "name": "TALAZOPARIB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2018-08-27", "completion_date": "2020-09-23", "has_results": true, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-11-11T02:35:49.060Z", "location_count": 97, "location_summary": "Gilbert, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 64 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Camarillo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03499353" }, { "nct_id": "NCT03470402", "title": "Decision Support for BRCA Testing in Ethnically Diverse Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "BRCA1 Mutation", "BRCA2 Mutation", "Ovarian Cancer" ], "interventions": [ { "name": "RealRisks", "type": "OTHER" }, { "name": "BNAV", "type": "OTHER" }, { "name": "iNYP", "type": "OTHER" }, { "name": "Standard Educational Material", "type": "OTHER" }, { "name": "High-Risk Message", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "21 Years to 75 Years · Female only" }, "enrollment_count": 276, "start_date": "2017-12-13", "completion_date": "2020-08-17", "has_results": false, "last_update_posted_date": "2021-04-19", "last_synced_at": "2026-11-11T02:35:49.060Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03470402" }, { "nct_id": "NCT05642221", "title": "Functional Near-Infrared Spectroscopy (fNIRS) Combined With Diffuse Correlation Spectroscopy (DCS) in Neurocognitive Disease as Compared to Healthy Neurotypical Controls", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Juvenile Neuronal Ceroid Lipofuscinosis", "Smith-Lemli-Opitz Syndrome", "Creatine Transporter Deficiency", "Niemann-Pick Disease Type C1" ], "interventions": [], "intervention_types": [], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "110 Years", "sex": "ALL", "summary": "6 Months to 110 Years" }, "enrollment_count": 73, "start_date": "2023-01-23", "completion_date": "2025-04-25", "has_results": false, "last_update_posted_date": "2026-11-10", "last_synced_at": "2026-11-11T02:35:49.060Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05642221" }, { "nct_id": "NCT01942993", "title": "The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Philip Friedlander", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2013-09", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2020-09-30", "last_synced_at": "2026-11-11T02:35:49.060Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01942993" }, { "nct_id": "NCT00668421", "title": "CEP-701 (Lestaurtinib) in Myelofibrosis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelofibrosis", "Essential Thrombocythemia", "Polycythemia Vera" ], "interventions": [ { "name": "CEP-701 (Lestaurtinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ronald Hoffman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2008-04", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2014-11-26", "last_synced_at": "2026-11-11T02:35:49.060Z", "location_count": 7, "location_summary": "Palo Alto, California • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ithaca", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00668421" } ] }